NCT02341027 is a NA clinical trial of Jadelle in Contraceptive Implant Utilization, sponsored by University of California, San Francisco.

Who is sponsoring NCT02341027?

NCT02341027 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT02341027?

Interventions in NCT02341027: Jadelle, Jadelle.

What condition does NCT02341027 study?

NCT02341027 studies Contraceptive Implant Utilization, Lactation.

Is NCT02341027 still recruiting?

NCT02341027 is currently completed. Last updated 11 February 2020.

Last reviewed 2020-02-11 · How we verify

NCT02341027

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immediate Versus Interval Postpartum Use of the Levonorgestrel Contraceptive Implants: a Randomized Controlled Trial

Completed NA Last updated 11 February 2020

What this trial tests

NA trial testing Jadelle in Contraceptive Implant Utilization in 205 participants. Completed in 1 June 2016.

Timeline

1 January 2015

Primary endpoint
1 June 2016

1 June 2016

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	205
Start date	1 January 2015
Primary completion	1 June 2016
Estimated completion	1 June 2016
Sites	1 location across Uganda

Drugs / interventions tested

Jadelle (LEVONORGESTREL) — full drug profile →
Jadelle (LEVONORGESTREL) — full drug profile →

Conditions studied

Contraceptive Implant Utilization — all drugs for Contraceptive Implant Utilization →
Lactation — all drugs for Lactation →

Sponsor

University of California, San Francisco

Who can join

Adults 18 to 50, female only, with Contraceptive Implant Utilization or Lactation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Implant utilization as measured by the proportion of women using LNG contraceptive implants at 6 months after delivery in women randomized to insertion within 5 days of delivery (immediate insertion) or 6-8 weeks after delivery (delayed insertion).
Time frame: 6 months

Sponsor's own description

This study will evaluate if immediate postpartum placement of a levonorgestrel (LNG) contraceptive implant within 5 days of delivery improves implant utilization at 6 months postpartum compared to implant placement at 6-8 weeks postpartum among women in Uganda.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immediate versus delayed postpartum use of levonorgestrel contraceptive implants: a randomized controlled trial in Uganda.
Averbach S, Kakaire O, Kayiga H, Lester F, et al · · 2017 · cited 11× · PMID 28610898 · DOI 10.1016/j.ajog.2017.06.005
The effect of immediate postpartum levonorgestrel contraceptive implant use on breastfeeding and infant growth: a randomized controlled trial.
Averbach S, Kakaire O, McDiehl R, Dehlendorf C, et al · · 2019 · cited 7× · PMID 30408456 · DOI 10.1016/j.contraception.2018.10.008

Verify or expand the search:

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02341027 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 11 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02341027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing